The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set a new standard in another patient group after proving its prowess ...

The Trump administration is doubling down on efforts to boost drug manufacturing in the U.S. with a new public-private initiative.

Vertex is narrowing development plans for Journavx and will specifically pursue a nod in diabetic peripheral neuropathy.

Monday, Bristol Myers Squibb helmsman Chris Boerner joined a growing list of life sciences leaders announcing major U.S. investments in the face of potential pharmaceutical import tariffs ...

Kansas City Chiefs tight end Travis Kelce has recently been the subject of rumors regarding his romantic involvement with singer Taylor Swift, but there is no doubt when it comes to his new ...

In many ways, 2023 has been a banner year for women. The blockbuster success of the Barbie movie ushered in a tsunami of girl power, women’s sports achieved new viewership highs during the Women ...

Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant.

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and ...

Novo Nordisk said that it has pulled its filing with the FDA for Wegovy to treat patients with heart failure and expects to resubmit in early 2025.

Bourla's predecessor Ian Read took the reins at Pfizer ahead of numerous patent losses, Bourla said at the J.P. Morgan Healthcare Conference in January, but after Lyrica’s patent cliff, “we ...

In short reprieve for pharma, commerce secretary says drug tariffs to come 'in the next month or two' ...

After recently placing a spotlight on Novo Nordisk’s "outrageous" U.S. | A new Senate HELP Committee report says GLP-1 drugs could "bankrupt our entire health care system" because of their high ...